LIR Life Sciences Income Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024
Cost of Revenue	0.01	0.02	-	-
Gross Profit	-0.01	-0.02	-	-
Selling, General & Admin	1.95	1.76	0.42	0.08
Research & Development	0.32	0.06	-	-
Operating Expenses	4.27	3.41	0.42	0.08
Operating Income	-4.28	-3.43	-0.42	-0.08
Currency Exchange Gain (Loss)	-0	-0	-	-
Other Non Operating Income (Expenses)	-0.42	-0.41	-	-
EBT Excluding Unusual Items	-4.7	-3.85	-0.42	-0.08
Asset Writedown	-0.1	-0.1	-	-
Other Unusual Items	0.05	0.05	-	-
Pretax Income	-4.75	-3.9	-0.42	-0.08
Net Income	-4.75	-3.9	-0.42	-0.08
Net Income to Common	-4.75	-3.9	-0.42	-0.08
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	26	24	5	0
Shares Outstanding (Diluted)	26	24	5	0
Shares Change	154.80%	331.53%	41648.94%	-
EPS (Basic)	-0.18	-0.17	-0.08	-6.33
EPS (Diluted)	-0.18	-0.17	-0.08	-6.33
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024
EBITDA	-4.27	-3.43	-	-
D&A For EBITDA	0.01	0	-	-
EBIT	-4.28	-3.43	-0.42	-0.08
Advertising Expenses	-	0.81	0.05	-